ALECTOR, a venture-backed biotech focused on Alzheimer's disease, scored a midpoint pricing outcome to raise US$175.8m in its IPO on Wednesday night at a US$1.3bn public valuation. The company priced 9.25m shares at US$19 after marketing at US$18-$20.
展开▼
